Grants(8)

A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tu
Active·2023·$0 / $560.9K·
External
Co-Investigator (COI)
ovarian cancer, combination therapy, platinum-resistant, peritoneal cancer, fallopian-tube cancer
Multicenter, Open-label, Phase 2 Study of Carboplatin Plus Mirvetuximab Soravtansine Followed by Mirvetuximab Soravtansine Continuation in Folate
Active·2023·$0 / $419.4K·
External
Co-Investigator (COI)
chemotherapy, antibody-drug conjugate, ovarian cancer, clinical trial, folate receptor
A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec followed by Platinum-doublet Chemotherapy and Bevacizumab Compared with Platinum-doublet Chemotherapy and Bevacizumab in Women
Active·2023·$0 / $270.2K·
External
Co-Investigator (COI)
clinical trials, cancer treatment, immunotherapy, chemotherapy, women's health
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platnum Maintenance Therapy for Participants with Recurrent, Platinum-Sensitive
2023·$0 / $217.6K·
External
Co-Investigator (COI)
cancer therapy, clinical trial, pharmacology, immunotherapy, drug development
A Phase 1/2 Dose Escalation and Dose Expansion Study of ZNc3 in Combination with Niraparib in Subjects with Platinum Resistant Ovarian Cancer
2023·$0 / $18.4K·
External
Co-Investigator (COI)
ovarian cancer, combination therapy, dose escalation, dose expansion, platinum-resistant

Page 1 of 2

People

Profile

Janiel Cragun

Collaboration(10)

Setsuko Chambers

Guang Yao

Hina Arif Tiwari

Mitzi Miranda

Carolyn Lane

Grants(8)

A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tu

Multicenter, Open-label, Phase 2 Study of Carboplatin Plus Mirvetuximab Soravtansine Followed by Mirvetuximab Soravtansine Continuation in Folate

A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec followed by Platinum-doublet Chemotherapy and Bevacizumab Compared with Platinum-doublet Chemotherapy and Bevacizumab in Women

A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platnum Maintenance Therapy for Participants with Recurrent, Platinum-Sensitive

A Phase 1/2 Dose Escalation and Dose Expansion Study of ZNc3 in Combination with Niraparib in Subjects with Platinum Resistant Ovarian Cancer

Publications(38)

Antiandrogen Flutamide-Induced Restoration of miR-449 Expression Mitigates Molecular Markers Associated with Ovarian Cancer Risk

Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study

Incidence of Hypersensitivity Reactions to Carboplatin or Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With or Without or Mutations

The utility of patient reported data in a gynecologic oncology clinic

Incidence of Hypersensitivity Reactions to Carboplatin in Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer with or without BRCA1 or BRCA2 Mutations

An Interdisciplinary program to prevent postoperative pneumonia: An Evidenced-Based Project.

Simple Patient Care Instructions Translate Best: Safety Guidelines for Physician Use of Google Translate

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma ARIEL2 Part 1) an international, multicentre, open-label, phase 2 trial

Refinement of prespecified cutoff for genomic loss of heterozygosity LOH) in ARIEL2 part 1: A phase 2 study of rucaparib in patients pts) with high grade ovarian carcinoma HGOC) abstract)

Assessment of the Role of Intraoperative Frozen Section in Guiding Surgical Staging for Endometrial Cancer